Claim Missing Document
Check
Articles

Found 2 Documents
Search

HUBUNGAN PENGETAHUAN, SIKAP DAN PERILAKU MAHASISWA MUSLIM DI EMPAT PERGURUAN TINGGI NEGERI DI KOTA MANADO TERHADAP OBAT HALAL Hakim, Abdul; Sulaiman Mappiasse Pake, Hamdy; Syahrir, Ach.; Sugihantoro, Hajar
Jurnal Kesehatan Vol 17 No 1 (2024): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v17i1.29116

Abstract

Tujuan penelitian ini adalah untuk mengetahui bagaimana hubungan antara pengetahuan, sikap dan perilaku mahasiswa muslim di empat perguruan tinggi negeri di Kota Manado terhadap obat halal. Metode penelitian yang digunakan adalah studi observasional analitik dengan pendekatan kuantitatif. Pengumpulan data penelitian dilakukan menggunakan kuesioneryang disebarkan via online menggunakan Google Form. Populasi penelitian ini adalah mahasiswa muslim di empat perguruan tinggi negeri di Kota Manado. Pengambilan sampel menggunakan purposive sampling dengan sampel sebanyak 100 responden. Hasil penelitian ini menunjukkan bahwa terdapat hubungan antara pengetahuan dan sikap mahasiswa muslim di empat perguruan tinggi negeri di Kota Manado terhadap obat halal (sig. 0,00 < 0,05) dengan keeratan sedang. Hubungan antara pengetahuan dan perilaku terhadap obat halal (sig. 0,00 < 0,05) dengan keeratan rendah. Hubungan antara sikap dan perilaku terhadap obat halal (sig. 0,00 < 0,05) dengan keeratan rendah. Terakhir, hubungan antara pengethuan dan sikap secara simultan terhadap perilaku terhadap obat halal (sig. 0,00 < 0,05) dengan keeratan sedang.
Cost Effectiveness Analysis of Hypertensive Therapy in Hypertensive Patients with Type 2 of Diabetes Mellitus at RSUD Dr. Soehadi Prijonegoro Sragen: Analisis Efektivitas Biaya Terapi Hipertensi pada Pasien Hipertensi dengan Diabetes Melitus Tipe 2 di RSUD dr. Soehadi Prijonegoro Sragen Jati, Alpian Rona Asmoro; Sugihantoro, Hajar; Syahrir, Ach.
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 11 No. 1 (2025): (March 2025)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/j24428744.2025.v11.i1.16955

Abstract

Background: Hypertension followed by type 2 diabetes mellitus is a major risk factor for various cardiovascular diseases and is one of the chronic degenerative diseases Hence, it requires long-lasting treatment therapy and high costs. Based on this, hypertensive patients with DM type 2 need special attention in order to get effective hypertensive therapy at minimum cost. Cost-effectiveness analysis is an analytical method for making decisions on the best alternative to the therapy used. Objectives: To determine the most cost-effective hypertensive therapy in hypertensive patients with DM type 2 diabetes who underwent pharmacoeconomic hospitalization with a cost-effectiveness analysis approach. Methods: This type of study is descriptive observational with a retrospective data collection method from January 2021 - June 2023. The data taken was 31 medical records data and bill fees that met the inclusion criteria. Results: The description of drug use in hypertensive patients with DM type 2 diabetes at RSUD Soehadi Prijonegoro Sragen consists of monotherapy (19.35%) and combination (80.65%). The effectiveness of monotherapy was highest in patients receiving amlodipine therapy (12.42 mmHg), while the effectiveness of the combination was highest in patients taking adalat oros + candesartan + bisoprolol + furosemide + clonidine (22,38 mmHg). From the calculation of the ACER value, it was found that the most cost-effective drug was amlodipine, which had an ACER value of Rp. 289,962 in monotherapy and amlodipine + candesartan with an ACER value of Rp. 262,626. Conclusions: The most widely used hypertension therapy is combination therapy; the drug with the highest effectiveness is adalat oros + candesartan + bisoprolol + furosemide + clonidine and the drug with the highest cost-effectiveness is amlodipine monotherapy and the combination of amlodipine + candesartan.